Follow Pfizer to never miss an important update.
Pfizer reached a research goal in its work with Nurix Therapeutics, triggering a 7 million dollar payment. The two companies are working on a new class of medicines called degrader antibody conjugates, which are designed to destroy specific proteins that help cancer grow. While the payment is small for a company of Pfizer's size, it shows steady progress in its effort to build a leading cancer-treatment business. Expanding its oncology portfolio is a key part of Pfizer's plan to replace revenue from older drugs that will soon lose their patent protection.
Source: GlobeNewsWire
Pfizer is locked in a legal battle with Poland and Romania over roughly 2 billion dollars in COVID-19 vaccines that the countries ordered but later refused to take. In an unusual move to secure payment, the company has targeted air-traffic control fees as a way to collect on the debt.
While the dollar amount is large, this is a known dispute over the tail end of the pandemic business. It highlights the friction as Pfizer tries to hold governments to their contracts even as demand for the shots has vanished. For long-term owners, the outcome is less about the company's future growth and more about how much of this old revenue it can eventually claw back.
Source: WSJ
HSBC raised its price target for Pfizer to $30, up from $28. This move puts their target slightly above the $28 average across other Wall Street firms. While the rating on the stock did not change, the higher target suggests a bit more confidence in the company's path forward. For a long-term owner, this is a routine adjustment rather than a major shift in view. The stock has been trading around $27.55, so the new target implies about 9 percent upside from current levels.
Source: HSBC
The U.S. Food and Drug Administration approved Pfizer’s updated vaccine designed to target the XFG variant, which is currently the most common version of the virus. This approval allows the company to begin distributing shots for the 2026-2027 respiratory virus season.
While Pfizer is moving away from its heavy reliance on pandemic-era sales, these annual boosters remain a steady part of its business. Success here depends on how many people choose to get vaccinated this year, which helps the company maintain a baseline of cash while it focuses on growing its newer cancer treatments.
Source: Reuters
Guggenheim analysts lowered their target for the stock from $35 to $31 while keeping a buy rating. This means they still think the company is a good investment but expect the stock price to rise less than they did before. The new target is still slightly above the current price of about $28. This change follows the company's recent earnings and reflects a more cautious view on how quickly the stock will climb. Most analysts currently have a target price of around $28, so Guggenheim remains more optimistic than the average.
Source: Guggenheim
Management consistently sets a bar they can clear, beating their own profit targets for eight straight quarters. It shows they have a firm handle on their costs even as COVID-related sales drop off.
| Expectation | |
|---|---|
| EPS | $0.77 |
| Revenue | $15.93B |